Differences in the Risk of Clinical Failure Between Thiopurine and Methotrexate in Bio-naïve Patients with Crohn's Disease: a Korean Nationwide Population-based Study

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2024 May 14

PMID 38741927

Authors

Yu Kyung Jun

Eunjeong Ji

Hye Ran Yang

Yonghoon Choi

Cheol Min Shin

Young Soo Park

Nayoung Kim

Dong Ho Lee

Hyuk Yoon

Affiliations

Soon will be listed here.

Abstract

Background: Although immunomodulators are widely prescribed in patients with Crohn's disease (CD), it is unclear whether there is a difference in treatment outcomes between thiopurines and methotrexate (MTX).

Objective: To compare the risk of clinical failure between thiopurines and MTX in bio-naïve patients with CD.

Design: Nationwide, population-based study.

Methods: We used claims data from the Korean National Health Insurance Service. After inverse probability of treatment weighting, logistic regression and Cox proportional hazard analyses were used to evaluate the risk of clinical failure in bio-naïve patients with CD treated with thiopurine (thiopurine group) or MTX (MTX group).

Results: Overall, 10,296 adult and pediatric patients with CD [9912 (96.3%) and 384 (3.7%) in the thiopurine and MTX groups, respectively] were included. The odds ratios (ORs) of failure to induce remission were significantly higher in the MTX group than in the thiopurine group [adjusted OR (aOR), 1.115; 95% confidence interval (CI), 1.045-1.190; = 0.001]. However, the opposite result was observed only in patients without concomitant steroid use: the MTX group had a lower risk of induction failure than the thiopurine group (aOR, 0.740; 95% CI, 0.673-0.813; < 0.001). The risk of overall maintenance failure was higher in the MTX group than in the thiopurine group [adjusted hazard ratio (aHR), 1.117; 95% CI, 1.047-1.191; = 0.001]. The risk of overall maintenance failure was higher in the standard-dose MTX group than in the low-dose MTX group (aHR, 1.296; 95% CI, 1.134-1.480; < 0.001). There was no significant difference in the risk of maintenance failure according to the administration route of MTX.

Conclusion: Thiopurine is more effective than MTX in inducing and maintaining remission in bio-naïve patients with CD; however, the concomitant use of steroids influences inducing remission.

References

Turner D, Doveh E, Cohen A, Wilson M, Grossman A, Rosh J . Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study. Gut. 2014; 64(12):1898-904. DOI: 10.1136/gutjnl-2014-307964. View

Wu E, Duan M, Han J, Zhang H, Zhou Y, Cao L . Patients with Crohn's Disease Undergoing Abdominal Surgery: Clinical and Prognostic Evaluation Based on a Single-Center Cohort in China. World J Surg. 2021; 46(2):450-460. DOI: 10.1007/s00268-021-06366-z. View

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007; 147(8):W163-94. DOI: 10.7326/0003-4819-147-8-200710160-00010-w1. View

Solberg I, Vatn M, Hoie O, Stray N, Sauar J, Jahnsen J . Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5(12):1430-8. DOI: 10.1016/j.cgh.2007.09.002. View

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert J, Raine T . ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2019; 14(1):4-22. DOI: 10.1093/ecco-jcc/jjz180. View

Austin P, Stuart E . Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34(28):3661-79. PMC: 4626409. DOI: 10.1002/sim.6607. View

Domenech E, Manosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y . Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol. 2008; 42(4):395-9. DOI: 10.1097/MCG.0b013e31802e6875. View

Kim J, Yun S, Hwang S, Shim J, Chae H, Lee Y . The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018; 61(5):135-149. PMC: 5976563. DOI: 10.3345/kjp.2018.61.5.135. View

Kariyawasam V, Selinger C, Katelaris P, Brian Jones D, McDonald C, Barr G . Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease. Inflamm Bowel Dis. 2014; 20(8):1382-90. DOI: 10.1097/MIB.0000000000000119. View

10.

Kyoung D, Kim H . Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research. J Lipid Atheroscler. 2022; 11(2):103-110. PMC: 9133780. DOI: 10.12997/jla.2022.11.2.103. View

11.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

12.

Parker R, Dixit A, Dixit A, Fraser A, Creed T, Probert C . Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment. Postgrad Med J. 2010; 86(1014):208-11. DOI: 10.1136/pgmj.2009.085787. View

13.

Vasudevan A, Parthasarathy N, Con D, Nicolaides S, Apostolov R, Chauhan A . Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 52(7):1174-1184. DOI: 10.1111/apt.16039. View

14.

Sandborn W . Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001; 48(5):591-2. PMC: 1728293. DOI: 10.1136/gut.48.5.591. View

15.

Hermida C, Moreno-Otero R . 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000; 12(11):1227-33. DOI: 10.1097/00042737-200012110-00010. View

16.

McDonald J, Wang Y, Tsoulis D, MacDonald J, Feagan B . Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2014; (8):CD003459. PMC: 7154581. DOI: 10.1002/14651858.CD003459.pub4. View

17.

Seinen M, Ponsioen C, de Boer N, Oldenburg B, Bouma G, Mulder C . Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013; 11(6):667-72. DOI: 10.1016/j.cgh.2012.12.026. View

18.

Ranjan M, Kumar P, Vuyyuru S, Kante B, Mundhra S, Golla R . Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis. J Crohns Colitis. 2023; 18(2):192-203. DOI: 10.1093/ecco-jcc/jjad135. View

19.

Kim J, Song H, Boo S, Kim H, Kang K, Na S . Thirty-year Trend in Inflammatory Bowel Disease on Jeju Island, South Korea. Korean J Gastroenterol. 2023; 81(6):243-252. DOI: 10.4166/kjg.2023.006. View

20.

Atia O, Friss C, Ledderman N, Greenfeld S, Kariv R, Daher S . Thiopurines Have Longer Treatment Durability than Methotrexate in Adults and Children with Crohn's Disease: A Nationwide Analysis from the epi-IIRN Cohort. J Crohns Colitis. 2023; 17(10):1614-1623. DOI: 10.1093/ecco-jcc/jjad076. View